Pathogenesis of thyroid eye disease: review and update on molecular mechanisms

被引:162
作者
Khong, Jwu Jin [1 ,2 ,3 ]
McNab, Alan A. [2 ,4 ]
Ebeling, Peter R. [1 ,5 ]
Craig, Jamie E. [6 ]
Selva, Dinesh [7 ]
机构
[1] Univ Melbourne, Western Hosp, North West Acad Ctr, St Albans, Vic, Australia
[2] Royal Victorian Eye & Ear Hosp, Orbital Plast & Lacrimal Unit, East Melbourne, Vic 3002, Australia
[3] Univ Melbourne, Dept Surg, Austin Hlth, Heidelberg, Vic, Australia
[4] Univ Melbourne, Ctr Eye Res Australia, East Melbourne, Vic, Australia
[5] Monash Univ, Sch Clin Sci, Dept Med, Clayton, Vic, Australia
[6] Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA 5001, Australia
[7] Univ Adelaide, South Australian Inst Ophthalmol, Adelaide, SA, Australia
关键词
GROWTH-FACTOR-I; HUMAN ORBITAL FIBROBLASTS; THYROTROPIN RECEPTOR EXPRESSION; INDUCE HYALURONAN SYNTHESIS; ENDOPEROXIDE H SYNTHASE-2; SEVERE GRAVES ORBITOPATHY; HEAT-SHOCK-PROTEIN; OXIDATIVE STRESS; T-CELLS; NATURAL-HISTORY;
D O I
10.1136/bjophthalmol-2015-307399
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Orbital changes in thyroid orbitopathy (TO) result from de novo adipogenesis, hyaluronan synthesis, interstitial oedema and enlargement of extraocular muscles. Cellular immunity, with predominantly CD4+ T cells expressing Th1 cytokines, and overexpression of macrophage-derived cytokines, perpetuate orbital inflammation. Orbital fibroblasts appear to be the major effector cells. Orbital fibroblasts express both thyrotropin receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R) at higher levels than normal fibroblasts. TSHR expression increases in adipogenesis; TSHR agonism enhances hyaluronan production. IGF-1R stimulation leads to adipogenesis, hyaluronan synthesis and production of the chemokines, interleukin (IL)-16 and Regulated on Activation, Normal T Cell Expression and Secreted, which facilitate lymphocyte trafficking into the orbit. Immune activation uses a specific CD40:CD154 molecular bridge to activate orbital fibroblasts, which secrete pro-inflammatory cytokines including IL-1 beta, IL-1 alpha, IL-6, IL-8, macrophage chemoattractant protein-1 and transforming growth factor-beta, to perpetuate orbital inflammation. Molecular pathways including adenylyl cyclase/cyclic adenosine monophosphate, phophoinositide 3 kinase/AKT/mammalian target of rapamycin, mitogen-activated protein kinase are involved in TO. The emergence of a TO animal model and a new generation of TSHR antibody assays increasingly point towards TSHR as the primary autoantigen for extrathyroidal orbital involvement. Oxidative stress in TO resulting from imbalances of the oxidation-reduction state provides a framework of understanding for smoking prevention, achieving euthyroidism and the use of antioxidants such as selenium. Progress has been made in the understanding of the pathogenesis of TO, which should advance development of novel therapies targeting cellular immunity, specifically the CD40:CD40 ligand interaction, antibody-producing B cells, cytokines, TSHR and IGF-1R and its signalling pathways. Further studies in signalling networks and molecular triggers leading to burnout of TO will further our understanding of TO.
引用
收藏
页码:142 / U175
页数:9
相关论文
共 122 条
[1]   Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments [J].
Abalovich, M ;
Llesuy, S ;
Gutierrez, S ;
Repetto, M .
CLINICAL ENDOCRINOLOGY, 2003, 59 (03) :321-327
[2]   Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy [J].
Aniszewski, JP ;
Valyasevi, RW ;
Bahn, RS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :776-780
[3]   Adalimumab as Steroid-Sparing Treatment of Inflammatory-Stage Thyroid Eye Disease [J].
Ayabe, Reed ;
Rootman, Dan B. ;
Hwang, Catherine J. ;
Ben-Artzi, Ami ;
Goldberg, Robert .
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2014, 30 (05) :415-419
[4]   Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: Potential autoantigen in Graves' ophthalmopathy [J].
Bahn, RS ;
Dutton, CM ;
Natt, N ;
Joba, W ;
Spitzweg, C ;
Heufelder, AE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :998-1002
[5]   Reevaluating thyrotropin receptor-induced mouse models of Graves' disease and ophthalmopathy [J].
Baker, G ;
Mazziotti, G ;
von Ruhland, C ;
Ludgate, M .
ENDOCRINOLOGY, 2005, 146 (02) :835-844
[6]   Clinical Utility of TSH Receptor Antibodies [J].
Barbesino, Giuseppe ;
Tomer, Yaron .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (06) :2247-2255
[7]   Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy [J].
Bartalena, L ;
Marcocci, C ;
Bogazzi, F ;
Manetti, L ;
Tanda, ML ;
Dell'Unto, E ;
Bruno-Bossio, G ;
Nardi, M ;
Bartolomei, MP ;
Lepri, A ;
Rossi, G ;
Martino, E ;
Pinchera, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (02) :73-78
[8]  
Bartley G B, 1994, Trans Am Ophthalmol Soc, V92, P477
[9]   Oxidative stress peripheral parameters in Graves' disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy [J].
Bednarek, J ;
Wysocki, H ;
Sowinski, J .
CLINICAL BIOCHEMISTRY, 2005, 38 (01) :13-18
[10]   The critical role of Shc in insulin-like growth factor-I-mediated mitogenesis and differentiation in 3T3-L1 preadipocytes [J].
Boney, CM ;
Gruppuso, PA ;
Faris, RA ;
Frackelton, AR .
MOLECULAR ENDOCRINOLOGY, 2000, 14 (06) :805-813